Skip to main content
main-content
Erschienen in: CME 6/2017

07.06.2017 | Diagnostik in der Endokrinologie | CME Fortbildung

So erkennen und behandeln Sie die Hyperthyreose

Update zur Diagnostik und Therapie der Schilddrüsenüberfunktion

verfasst von: Prof. Dr. med. Matthias Schmidt

Erschienen in: CME | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die manifeste Hyperthyreose ist definiert als Erhöhung des Werts von freiem Triiodthyronin (fT3) und / oder freiem Thyrosin (fT4) über den oberen Normbereich bei supprimiertem basalen Thyreoidea-stimulierendem Hormon (TSH). Sie ist zunächst eine Labordefinition mit vielfältigen Ursachen. Für eine richtige Diagnose sind neben der Anamnese und klinischen Untersuchung die Bestimmung von weiteren Laborwerten, eine Ultraschalluntersuchung und oftmals auch eine Szintigrafie erforderlich. Häufige Differenzialdiagnosen sind die Immunhyperthyreose Morbus Basedow und die Schilddrüsenautonomie sowie transiente hyperthyreote Phasen bei Thyreoitiden. Medikamenten‑induzierte Hyperthyreosen präsentieren sich mit zunehmender Häufigkeit, vor allem durch neue onkologische Behandlungsansätze mit immunmodulierenden Substanzen. Die Herausforderung besteht in der richtigen Diagnosestellung, weil sich hieraus differenzierte Therapieansätze ergeben. Die Behandlung berücksichtigt den individuellen Patienten mit seinen Beschwerden, Begleiterkrankungen und Wünschen.
Literatur
1.
Zurück zum Zitat Klaua M, Bauch KH, Ulrich FE, Hänsgen K: Hyperthyreoseinzidenz im Bezirk Halle vor und nach Einführung der allgemeinen Iodprophylaxe. Z Gesamte Inn Med 1991; 46: 573–580 PubMed Klaua M, Bauch KH, Ulrich FE, Hänsgen K: Hyperthyreoseinzidenz im Bezirk Halle vor und nach Einführung der allgemeinen Iodprophylaxe. Z Gesamte Inn Med 1991; 46: 573–580 PubMed
2.
Zurück zum Zitat Mostbeck A, Galvan G, Bauer P et al.: The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990. Eur J Nucl Med 1998; 25: 367–374. CrossRefPubMed Mostbeck A, Galvan G, Bauer P et al.: The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990. Eur J Nucl Med 1998; 25: 367–374. CrossRefPubMed
3.
Zurück zum Zitat Völzke H, Lüdemann J, Robinson DM, et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13: 803–810 CrossRefPubMed Völzke H, Lüdemann J, Robinson DM, et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13: 803–810 CrossRefPubMed
4.
Zurück zum Zitat Brabant, Kahaly, Schicha, Reiners. Dtsch Ärztebl 2006; 103(31-32): A2110–A2115 Brabant, Kahaly, Schicha, Reiners. Dtsch Ärztebl 2006; 103(31-32): A2110–A2115
5.
Zurück zum Zitat Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clijn Endocrinol Metab 2014; 99: 923–931 CrossRef Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clijn Endocrinol Metab 2014; 99: 923–931 CrossRef
6.
Zurück zum Zitat Hanley P et al. Thyroid Disorders in Children and Adolescents — A Review. JAMA Pediatr 2016; 170: 1008–1019. doi:10.1001/jamapediatrics.2016.0486 CrossRefPubMed Hanley P et al. Thyroid Disorders in Children and Adolescents — A Review. JAMA Pediatr 2016; 170: 1008–1019. doi:10.1001/jamapediatrics.2016.0486 CrossRefPubMed
7.
Zurück zum Zitat Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26: 1343–1421. CrossRefPubMed Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26: 1343–1421. CrossRefPubMed
8.
Zurück zum Zitat Eckstein A, Dekowski D, Führer-Sakel D, Berchner-Pfannschmidt U, Esser J. Endokrine Orbitopathie. Ophthalmologe 2016; 113: 349–366 CrossRefPubMed Eckstein A, Dekowski D, Führer-Sakel D, Berchner-Pfannschmidt U, Esser J. Endokrine Orbitopathie. Ophthalmologe 2016; 113: 349–366 CrossRefPubMed
9.
Zurück zum Zitat Ehrenkranz J, Bach PR, Snow GL, Schneider A, Lee JL, Ilstrup S, Bennett ST, Benvenga S. Circadian and Circannual Rhythms in Thyroid Hormones: Determining the TSH and Free T4 Reference Intervals Based Upon Time of Day, Age, and Sex. Thyroid 2015; 25: 954–961 CrossRefPubMed Ehrenkranz J, Bach PR, Snow GL, Schneider A, Lee JL, Ilstrup S, Bennett ST, Benvenga S. Circadian and Circannual Rhythms in Thyroid Hormones: Determining the TSH and Free T4 Reference Intervals Based Upon Time of Day, Age, and Sex. Thyroid 2015; 25: 954–961 CrossRefPubMed
10.
Zurück zum Zitat Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008; 31: 866–872 CrossRefPubMed Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008; 31: 866–872 CrossRefPubMed
11.
Zurück zum Zitat Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 2005; 153: 489–498 CrossRefPubMed Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 2005; 153: 489–498 CrossRefPubMed
12.
Zurück zum Zitat Führer D, Holzapfel HP, Wonerow P et al Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82: 3885–3891 PubMed Führer D, Holzapfel HP, Wonerow P et al Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. J Clin Endocrinol Metab 1997; 82: 3885–3891 PubMed
13.
Zurück zum Zitat Führer D, Musholt T, Schmid KW. Molekulare Pathogenese von Schilddrüsenknoten. Der Nuklearmediziner 2016; 39: 160–165 CrossRef Führer D, Musholt T, Schmid KW. Molekulare Pathogenese von Schilddrüsenknoten. Der Nuklearmediziner 2016; 39: 160–165 CrossRef
14.
Zurück zum Zitat Kleinau G 1, Neumann S, Grüters A et al. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev 2013; 34: 691–724 CrossRefPubMedPubMedCentral Kleinau G 1, Neumann S, Grüters A et al. Novel insights on thyroid-stimulating hormone receptor signal transduction. Endocr Rev 2013; 34: 691–724 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Krohn K, Führer D, Bayer Y et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005; 26: 504–524 CrossRefPubMed Krohn K, Führer D, Bayer Y et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005; 26: 504–524 CrossRefPubMed
16.
Zurück zum Zitat Krohn K, Führer D, Holzapfel HP et al. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 1998; 83: 130–134 PubMed Krohn K, Führer D, Holzapfel HP et al. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 1998; 83: 130–134 PubMed
17.
Zurück zum Zitat De Sanctis L, Galliano I, Montanari P, Matarazzo P, Tessaris D, Bergallo M. Combining Real-Time COLD- and MAMA-PCR TaqMan Techniques to Detect and Quantify R201 GNAS Mutations in the McCune-Albright Syndrome. Horm Res Paediatr 2017 DOI: 10.1159/000463384 De Sanctis L, Galliano I, Montanari P, Matarazzo P, Tessaris D, Bergallo M. Combining Real-Time COLD- and MAMA-PCR TaqMan Techniques to Detect and Quantify R201 GNAS Mutations in the McCune-Albright Syndrome. Horm Res Paediatr 2017 DOI: 10.1159/000463384
18.
Zurück zum Zitat Bähre M, Hilgers R, Lindemann C, Emrich D: Thyroid autonomy: sensitive detection in vivo and estimation of its functional relevance using quantified high-resolution scintigraphy. Acta Endocrinol (Copenh) 1988; 117: 145–153. Bähre M, Hilgers R, Lindemann C, Emrich D: Thyroid autonomy: sensitive detection in vivo and estimation of its functional relevance using quantified high-resolution scintigraphy. Acta Endocrinol (Copenh) 1988; 117: 145–153.
19.
Zurück zum Zitat Görges R, Kandror T, Kuschnerus S et al. Szintigraphisch mehranreichernde Schilddrüsenknoten gehen überwiegend mit normwertigem TSH einher. Nuklearmedizin 2011; 50: 179–188 CrossRefPubMed Görges R, Kandror T, Kuschnerus S et al. Szintigraphisch mehranreichernde Schilddrüsenknoten gehen überwiegend mit normwertigem TSH einher. Nuklearmedizin 2011; 50: 179–188 CrossRefPubMed
20.
Zurück zum Zitat Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249–1252. CrossRefPubMed Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249–1252. CrossRefPubMed
21.
Zurück zum Zitat Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J 2015; 4: 149–163 CrossRefPubMedPubMedCentral Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J 2015; 4: 149–163 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Marine D, C. H. Lenhart CH. Pathological anatomy of exophthalmic goiter. Arch Intern Med (Chicago) 1911; 8: 265–316. CrossRef Marine D, C. H. Lenhart CH. Pathological anatomy of exophthalmic goiter. Arch Intern Med (Chicago) 1911; 8: 265–316. CrossRef
23.
Zurück zum Zitat Charkes DN. Graves’ disease with functioning nodules (Marine-Lenhart syndrome). J Nucl Med 1972; 13: 885–892 PubMed Charkes DN. Graves’ disease with functioning nodules (Marine-Lenhart syndrome). J Nucl Med 1972; 13: 885–892 PubMed
24.
Zurück zum Zitat Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98: 3671–3677 CrossRefPubMedPubMedCentral Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98: 3671–3677 CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 2013; 98: 4776–4783 CrossRefPubMed Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 2013; 98: 4776–4783 CrossRefPubMed
26.
Zurück zum Zitat Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, Kunii Y, Mukasa K, Ito K, Ito K. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab 2012; 97: E49–53 CrossRefPubMed Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, Kunii Y, Mukasa K, Ito K, Ito K. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab 2012; 97: E49–53 CrossRefPubMed
27.
Zurück zum Zitat Felicilda-Reynaldo RF, Kenneally M. Antithyroid Drugs for Hyperthyroidism. Medsurg Nurs. 2016; 25: 50–54. PubMed Felicilda-Reynaldo RF, Kenneally M. Antithyroid Drugs for Hyperthyroidism. Medsurg Nurs. 2016; 25: 50–54. PubMed
28.
Zurück zum Zitat Dietlein M, Grünwald F, Schmidt M, Schneider P, Verburg FA, Luster M. [Radioiodine therapy for benign thyroid diseases (version 5). German Guideline]. Nuklearmedizin. 2016 Dec 6;55(6): 213–220 CrossRefPubMed Dietlein M, Grünwald F, Schmidt M, Schneider P, Verburg FA, Luster M. [Radioiodine therapy for benign thyroid diseases (version 5). German Guideline]. Nuklearmedizin. 2016 Dec 6;55(6): 213–220 CrossRefPubMed
29.
Zurück zum Zitat Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H. Incidence of postradioiodine immunogenic hyperthyroidism/Graves’ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid. 2006; 16: 281–288 CrossRefPubMed Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H. Incidence of postradioiodine immunogenic hyperthyroidism/Graves’ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid. 2006; 16: 281–288 CrossRefPubMed
30.
Zurück zum Zitat Musholt TJ, Clerici T, Dralle H, Frilling A, Goretzki PE, Hermann MM, Kussmann J, Lorenz K, Nies C, Schabram J, Schabram P, Scheuba C, Simon D, Steinmüller T, Trupka AW, Wahl RA, Zielke A, Bockisch A, Karges W, Luster M, Schmid KW; Interdisciplinary Task Force Guidelines of the German Association of Endocrine Surgeons. German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg. 2011; 396: 639–649 CrossRefPubMed Musholt TJ, Clerici T, Dralle H, Frilling A, Goretzki PE, Hermann MM, Kussmann J, Lorenz K, Nies C, Schabram J, Schabram P, Scheuba C, Simon D, Steinmüller T, Trupka AW, Wahl RA, Zielke A, Bockisch A, Karges W, Luster M, Schmid KW; Interdisciplinary Task Force Guidelines of the German Association of Endocrine Surgeons. German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. Langenbecks Arch Surg. 2011; 396: 639–649 CrossRefPubMed
31.
Zurück zum Zitat Dietrich JW. Thyreotoxische Krise. Med Klein Intensivmed Notfmed 2012; 107: 448–453 CrossRef Dietrich JW. Thyreotoxische Krise. Med Klein Intensivmed Notfmed 2012; 107: 448–453 CrossRef
32.
Zurück zum Zitat Schmidt M. Schilddrüse und Schwangerschaft. Der Nuklearmediziner 2016; 39: 132–136 CrossRef Schmidt M. Schilddrüse und Schwangerschaft. Der Nuklearmediziner 2016; 39: 132–136 CrossRef
33.
Zurück zum Zitat Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21: 1081–1125. CrossRefPubMedPubMedCentral Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W; American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21: 1081–1125. CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Patil-Sisodia K, Mestman JH. Graves hyperthyroidism and pregnancy: a clinical update. Endocr Pract 2010; 16: 118–129 CrossRefPubMed Patil-Sisodia K, Mestman JH. Graves hyperthyroidism and pregnancy: a clinical update. Endocr Pract 2010; 16: 118–129 CrossRefPubMed
35.
Zurück zum Zitat Anderson SL, Olsen J, Laurberg P. Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab 2016; 101: 1606–1614 CrossRef Anderson SL, Olsen J, Laurberg P. Antithyroid drug side effects in the population and in pregnancy. J Clin Endocrinol Metab 2016; 101: 1606–1614 CrossRef
36.
Zurück zum Zitat Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012; 97: 2396–2403 CrossRefPubMed Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012; 97: 2396–2403 CrossRefPubMed
37.
Zurück zum Zitat Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid 2014; 24: 1533–1540 CrossRefPubMedPubMedCentral Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid 2014; 24: 1533–1540 CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Nicholson WK, Robinson KA, Smallridge RC, Ladenson PW, Powe NR. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid. 2006; 16: 573–82 CrossRefPubMed Nicholson WK, Robinson KA, Smallridge RC, Ladenson PW, Powe NR. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid. 2006; 16: 573–82 CrossRefPubMed
39.
Zurück zum Zitat De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 2543–2565 CrossRefPubMed De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 2543–2565 CrossRefPubMed
40.
41.
Zurück zum Zitat Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman W, Laurberg P, Lazarus JH, Mandel SJ, Peeters R, Sullivan S. 2016 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. Thyroid 2017 Jan 6. doi: 10.1089/thy.2016.0457 Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman W, Laurberg P, Lazarus JH, Mandel SJ, Peeters R, Sullivan S. 2016 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and the Postpartum. Thyroid 2017 Jan 6. doi: 10.1089/thy.2016.0457
42.
Zurück zum Zitat Stagnaro-Green A, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Negro R. High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy. J Clin Endocrinol Metab 2011; 96: 652–657 CrossRefPubMed Stagnaro-Green A, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Negro R. High rate of persistent hypothyroidism in a large-scale prospective study of postpartum thyroiditis in southern Italy. J Clin Endocrinol Metab 2011; 96: 652–657 CrossRefPubMed
43.
Zurück zum Zitat Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab 2007; 92: 1263–1268 CrossRefPubMed Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab 2007; 92: 1263–1268 CrossRefPubMed
44.
Zurück zum Zitat Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: co-sponsored by American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18: 988–1028 CrossRefPubMed Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: co-sponsored by American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18: 988–1028 CrossRefPubMed
45.
Zurück zum Zitat Fricke E. Prognosebeurteilung bei geplanter Kontrastmittelexposition. Der Nuklearmediziner 2004; 27: 73–77 CrossRef Fricke E. Prognosebeurteilung bei geplanter Kontrastmittelexposition. Der Nuklearmediziner 2004; 27: 73–77 CrossRef
46.
Zurück zum Zitat Fricke E, Fricke H, Esdorn E, Kammeier A, Lindner O, Kleesiek K, Horstkotte D, Burchert W. Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: a prospective study of patients with low thyrotropin. J Clin Endocrinol Metab 2004, 89: 6092–6096 CrossRefPubMed Fricke E, Fricke H, Esdorn E, Kammeier A, Lindner O, Kleesiek K, Horstkotte D, Burchert W. Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: a prospective study of patients with low thyrotropin. J Clin Endocrinol Metab 2004, 89: 6092–6096 CrossRefPubMed
47.
Zurück zum Zitat De Leo S1, Lee SY2, Braverman LE Hyperthyroidism. Lancet. 2016 Aug 27;388(10047):906–18. doi: 10.1016/S0140-6736(16)00278-6. Epub 2016 Mar 30. CrossRefPubMedPubMedCentral De Leo S1, Lee SY2, Braverman LE Hyperthyroidism. Lancet. 2016 Aug 27;388(10047):906–18. doi: 10.1016/S0140-6736(16)00278-6. Epub 2016 Mar 30. CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Mammen JS, Ghazarian SR, Pulkstenis E, Subramanian GM, Rosen A, Ladenson PW. Phenotypes of interferon-a-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex. J Clin Endocrinol Metab 2012; 97: 3270–3276 CrossRefPubMed Mammen JS, Ghazarian SR, Pulkstenis E, Subramanian GM, Rosen A, Ladenson PW. Phenotypes of interferon-a-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex. J Clin Endocrinol Metab 2012; 97: 3270–3276 CrossRefPubMed
49.
Zurück zum Zitat Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 2016; 28: 278–287 CrossRefPubMed Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 2016; 28: 278–287 CrossRefPubMed
50.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26: 1–133. CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26: 1–133. CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Schneider C, Dietlein M, Eschner W, Schmidt M, Kahraman D, Kobe C. Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer. Exp Clin Endocrinol Diabetes. 2012; 120: 160–163 CrossRefPubMed Schneider C, Dietlein M, Eschner W, Schmidt M, Kahraman D, Kobe C. Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer. Exp Clin Endocrinol Diabetes. 2012; 120: 160–163 CrossRefPubMed
Metadaten
Titel
So erkennen und behandeln Sie die Hyperthyreose
Update zur Diagnostik und Therapie der Schilddrüsenüberfunktion
verfasst von
Prof. Dr. med. Matthias Schmidt
Publikationsdatum
07.06.2017
Verlag
Springer Medizin
Erschienen in
CME / Ausgabe 6/2017
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI
https://doi.org/10.1007/s11298-017-5982-5

Weitere Artikel der Ausgabe 6/2017

CME 6/2017 Zur Ausgabe

Neu im Fachgebiet Allgemeinmedizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Allgemeinmedizin und bleiben Sie gut informiert – ganz bequem per eMail.